Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy

Register of interests (PDF 138 KB)

Final draft guidance

Final draft guidance (PDF 253 KB)

Committee papers (PDF 6.19 MB)

Public committee slides (PDF 989 KB)

Equality impact assessment (PDF Version) (PDF 144 KB)

Committee meeting: 1

Supporting documentation Register of interests (PDF 138 KB)

Final scope (PDF 203 KB)

Final stakeholder list (PDF 191 KB)

Draft scope and provisional stakeholder list comments table (post-referral) (PDF 401 KB)

Equality impact assessment (Scoping) (PDF 129 KB)

Supporting documentation - draft scope (PDF 215 KB)

Provisional Stakeholder List (post-referral) (PDF 192 KB)

Final appraisal document - TA598 (PDF 264 KB)

Committee papers - TA598 (PDF 8.7 MB)

Public committee slides - TA598 (PDF 544 KB)

Managed access agreement - TA598 (PDF 365 KB)

Equality impact assessment - TA598 (PDF 140 KB)

Final guidance - TA598 (PDF 127 KB)

Final scope - TA598 (PDF 247 KB)

Final stakeholder list - TA598 (PDF 257 KB)

Equality impact assessment (Scoping) - TA598 (PDF 175 KB)

NICE's response to comments on the draft scope and provisional stakeholder list - TA598 (PDF 178 KB)